Vandria S.A.

https://www.vandria.com

LinkedIn: https://www.linkedin.com/company/vandria-sa

Vandria is at the vanguard of mitochondrial therapeutics. It is developing first-in-class mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases. Its lead program, VNA-318 is a brain-penetrant, patent-protected, mitophagy inducer which has been shown to acutely improve memory and learning and to have strong disease-modifying effects in models of neurodegenerative disease such as Alzheimer’s and Parkinson’s Disease. VNA-318 is expected to enter the clinic in Q2 2024. The company is also developing mitophagy-inducing small molecules to address muscle, lung, and liver diseases. A separate program targets ferroptosis, a form of cell death implicated in neurodegenerative diseases and ischemia reperfusion injury. Based in Lausanne Switzerland, Vandria was spun out of Amazentis SA in 2021 by its founders Patrick Aebischer, Chris Rinsch, and Johan Auwerx. The company has raised $20.6M (CHF18M) in venture finance. Its lead investor is ND Capital. *

	Start	2021-09-23 established (s-off)
	Predecessor	Amazentis S.A.
	Industry	VNA-318 (Vandria)
	Industry 2	drug development
	Person	Dugi, Klaus (Vandria 2021– CEO before Boehringer + Ferring)
	Person 2	Aebischer, Patrick (Ecole Polytechnique Fédérale 200808)

	Region	Lausanne VD
	Country	Switzerland
	City	1015 Lausanne VD
		Address record changed: 2023-12-18

Basic data	Employees	n. a.

		* Document for »About Section«: Vandria S.A.. (12/14/23). "Press Release: Vandria Announces $20.6M (CHF18M) Series A Financing Led by ND Capital to Drive CNS Clinical Program and Mitochondrial Therapeutics Platform". Lausanne.

		Record changed: 2025-03-16

Picture EBD Group ChinaBio Partnering Forum 2025 Shanghai 650x200px

More documents for Vandria S.A.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)